Form 4: Avid Bioservices Director Gregory Sargen Reports Stock Transactions

Director Gregory Sargen of Avid Bioservices, Inc. reports the vesting and acquisition of restricted stock units.

Summary

• Gregory Sargen, a director at Avid Bioservices, Inc., reported transactions involving restricted stock units (RSUs).
• On December 14, 2024, 26,756 RSUs granted in 2023 vested, converting into common stock.
• Also on December 14, 2024, Sargen was granted 8,147 new RSUs as part of the annual equity award program.
• The newly granted RSUs will vest on December 14, 2025, contingent on continuous service.

Sentiment

Score: 7

Explanation: The document reflects routine transactions related to director compensation, which is generally neutral to positive. The vesting of RSUs is a positive event for the director, and the grant of new RSUs indicates continued alignment with the company's goals.

Positives

• The vesting of RSUs indicates the completion of a vesting period for previously granted equity.
• The grant of new RSUs aligns with the company's director compensation program.

Future Outlook

The newly granted RSUs will vest on December 14, 2025, contingent on the director's continued service.

Industry Context

This is a standard disclosure of stock transactions by a company director, which is common practice in publicly traded companies.

Comparison to Industry Standards

• Equity compensation, such as RSUs, is a common practice for directors in publicly traded companies like Avid Bioservices.
• The vesting schedules and grant sizes are typical for director compensation packages, aligning with industry norms for incentivizing long-term commitment and performance.

Stakeholder Impact

• The vesting of RSUs may have a minor dilutive effect on existing shareholders.
• The grant of new RSUs aligns the director's interests with those of the shareholders.

Key Dates

Keywords

Avid Bioservices, Director, Gregory Sargen, Restricted Stock Units, RSU, Equity Compensation, Vesting, Stock Transaction